Providing patients and customers with
uncompromising quality and value for almost 40 years
Par is a specialty pharmaceutical company that develops, manufacture and markets innovative and cost-effective pharmaceuticals that help improve patient quality of life. Par Pharmaceutical offers a line of high barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands. Par Sterile Products develops, manufactures and markets both branded and generic aseptic injectable pharmaceuticals.
At Par, our most important resource is the talent and dedication of our nearly 1,900 employees, each of whom is part of a culture that values integrity, customer focus, teamwork and performance. In creating a climate that encourages collaboration, Par has become the partner of choice within its industry and has built a diverse network of strategic partnerships with dozens of companies. Headquartered in Woodcliff Lake, New Jersey, Par has manufacturing and R&D facilities in Chestnut Ridge, New York, Irvine, California, Rochester, Michigan, Stratford, Connecticut and Chennai, India.
|03/30/15||Par Specialty Pharmaceuticals Launches Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device Along with Nascobal® Nutrition Direct™ Program|
|One Spray per Device, Without the Need for Priming, Provides Greater Ease of Use
Nascobal® Nutrition Direct™ Program Designed to Make
Lifelong Nutritional Support as Simple as Possible
Chestnut Ridge, NY, March 30, 2015 – Par Specialty Pharmaceuticals (formerly Strativa Pharmaceuticals) today announced the launch of Nascobal® Nasal Spray in a single-use device. Nascobal® is a prescription vitamin B12 supplement administered as one spray, one nostril, once a week. Each single-use ... |
|03/13/15||Par Pharmaceutical Files Registration Statement for Initial Public Offering|
|Chestnut Ridge, NY, March 13, 2015 – Par Pharmaceutical Holdings, Inc. (collectively with its subsidiaries, “Par”) today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered by Par Pharmaceutical Holdings and its shareholders, and the price range for the offering, have not yet been determined.
Par expects to use the net proceeds it receiv... |
|03/05/15||Par Pharmaceutical Announces Fourth-Quarter and Full-Year 2014 |
|Chestnut Ridge, NY, March 6, 2015 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, March 13, 2015 at 2:00 p.m. EDT to review its results of operations for the fourth quarter and full year ended December 31, 2014. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission and will make certain other information available on its website by follow... |
|11/12/14||Par Pharmaceutical Announces First FDA Approval of Vasostrict™ (vasopressin injection, USP)|
|Chestnut Ridge, NY, Nov. 12, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has received approval for its New Drug Application (NDA) for Vasostrict™ (vasopressin injection, USP) 20 units/mL from the U.S. Food and Drug Administration (FDA) pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Par’s Vasostrict™ is the first and only vasopressin injection, USP, product with an NDA approved by the FDA. Vasostrict™ is indicated to increase blood ... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.